Comparison
Piracetam vs Noopept
Piracetam
The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. A cyclic derivative of GABA and the founding member of the racetam family.
Noopept
Russian-developed proline-containing dipeptide ~1000x more potent than piracetam by weight. Often grouped with racetams.
| Field | Piracetam | Noopept |
|---|---|---|
| Category | racetam | peptide |
| Dose range | 1200–4800mg | 10–30mg |
| Half-life | 5h | 0.5h |
| Onset | 45min | 20min |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USUnscheduled | USUnscheduled |
| PubMed refs | 1200 | 90 |
The comparison in plain English
Both modulate AMPA receptors and support cholinergic function, but Noopept is roughly 1000x more potent by weight and acts through a partially different mechanism, it metabolises to cycloprolylglycine, an endogenous neuropeptide that upregulates BDNF and NGF.
Bottom line
Noopept gives a stronger, faster effect at much smaller doses, with the added BDNF/NGF axis. Piracetam is gentler, better-characterised, and the safer first racetam.
Choose Piracetam if
You want a well-known starting point with decades of clinical evidence. Pair with Alpha-GPC.
Choose Noopept if
You want a more pronounced acute effect (20–40 minute onset), BDNF/NGF upregulation, or you are sensitive to capsule volume. 10–30mg.